Respondents	No. of respondents	No. of responses/respondent	Avg. burden/response (in hours)
Current Patients	8400	1	0.19
Discharged Patients	8400	1	0.214

8. National Hospital Discharge Survey—(0920–0212) Extension—The National Hospital Discharge Survey (NHDS), which has been conducted continuously by the National Center for Health Statistics, CDC, since 1965, is the principal source of data on inpatient utilization of short-stay, non-Federal hospitals and is the only annual source of nationally representative estimates on the characteristics of discharges, the lengths of stay, diagnoses, surgical and non-surgical procedures, and the patterns of use of care in hospitals in various regions of the country. It is the benchmark against which special programmatic data sources are compared. Data collected through the NHDS are essential for evaluating health status of the population, for the planning of programs and policy to elevate the health status of the Nation, for studying morbidity trends, and for research activities in the health field. NHDS data have been used extensively in the production of goals for the Year 2000 Health Objectives and the subsequent monitoring of these goals. In addition, NHDS data provide annual updates for numerous tables in the Congressionally-mandated NCHS report, Health, United States. Data from the NHDS are collected annually on approximately 250,000 discharges from a nationally representative sample of noninstitutional hospitals exclusive of Federal hospitals. The data items collected are the basic core of variables contained in the Uniform Hospital Discharge Data Set (UHDDS). Data for approximately half of the responding hospitals are abstracted from medical records while the remainder of the hospitals supply data through commercial abstract service organizations, state data systems, in-house tapes or printouts.

Respondents	No. of respondents	No. of responses/respondent	Avg. burden/response (in hours)
Primary Procedure Hospitals	77	251	0.083
Alternate Procedure Hospitals	136	250	0.016
Update (Abstract Service Hospitals)	150	2	0.033
Quality Control Forms (Hospitals)	50	40	0.016
Induction Forms (Hospitals)	40	1	2

9. Cost and Impact of Illnesses and Injuries Associated with Child Care Attendance—New—This is a longitudinal follow-up telephone survey of parents of children attending large (>15 children/center) day care centers and family day care homes (<7 children) in order to (1) determine the extent to which the size of day care centers are associated with the rates of illnesses and injuries for children attending day care; (2) to estimate the costs of illnesses and injuries for children attending small and large day care centers; (3) to compare the health of the family members of children attending small versus large day care centers; and, (4) to estimate the costs of illnesses for the family members of children attending small versus large day care centers. The analyses of the proposed survey data will allow CDC to evaluate the relative costs and benefits of attending small as opposed to large day care centers. The information will provide timely and valuable data to policy makers, medical professionals and scientists. The total burden will be 693 hours; there will be 272 respondents, and 12 interviews per respondent (one 35-minute interview and eleven 10-minute interviews). The study is proposed to last one year.

Respondents	No. of respondents	No. of responses/respondent	Avg. burden/response (in hours)
Parents (Monthly)	272	11	0.167
Parents (Annual)	272	1	0.583

Dated: August 14, 1995.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–20550 Filed 8–17–95; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

[Docket No. 91N–0450]

Guideline for Quality Assurance in Blood Establishments; Availability; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of July 14, 1995 (60 FR 36290). The document announced the availability of a guideline entitled ''Guideline for Quality Assurance in Blood Establishments.'' The guideline is intended to assist manufacturers of blood and blood components in developing quality assurance (QA) programs that are consistent with recognized principles of QA and current good manufacturing practice. The document was published with some errors. This document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Sharon A. Carayiannis, Center for Biologics Evaluation and Research (HFM–635), Food and Drug Administration,1401 Rockville Pike, Rockville, MD 20852, 301–594–3074.

In FR Doc. 95–17346, appearing on page 36290 in the **Federal Register** of Friday, July 14, 1995, the following corrections are made:

On page 36290, in the second column, under the **ADDRESSES** caption, in lines 25 and 34, ''CDV2.CBER.FDA.GOV'' is corrected to read ''CDVS2.CDER.FDA.GOV'', and on the same page, in the third column, under the **SUPPLEMENTARY INFORMATION** caption, in line 23, ''July 14, 1995,'' is corrected to read ''July 11, 1995''.

Dated: August 14, 1995.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 95–20565 Filed 8–17–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95C–0211]

Pilkington Barnes Hind; Filing of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Pilkington Barnes Hind has filed a petition proposing that the color additive regulations be amended to provide for the safe use of 2-[[2,5-diethoxy-4-[(4-methylphenyl)thio]phenyl]azo]-1,3,5-benzenetriol to tint soft (hydrophilic) contact lenses.

DATES: Written comments on the petitioner's environmental assessment by September 18, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Diane E. Robertson, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3089.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 721(b)(5) (21 U.S.C. 379e(b)(5))), notice is given that a color additive petition (CAP 5C0246) has been filed by Pilkington Barnes Hind, 810 Kifer Rd., Sunnyvale, CA 94086–5200. The petition proposes to amend the color additive regulations in § 73.3115 *2-[[2,5-Diethoxy- 4-[(4-methylphenyl)thio]phenyl]azo]-1,3,5-benzenetriol* (21 CFR 73.3115) to provide for the safe use of the color additive to tint soft (hydrophilic) contact lenses.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 18, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 7, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–20562 Filed 8–17–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95F–0201]

Huls Aktiengesellschaft (Huls AG); Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Huls Aktiengesellschaft (Huls AG), has filed a petition proposing that the food additive regulations be amended to provide for the safe use of poly-(trimethylhexamethylene terephthalamide) as components of articles intended for food-contact use.

DATES: Written comments on the petitioner's environmental assessment by September 18, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3086.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec.409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 2B4328) has been filed by Huls Aktiengesellschaft (Huls AG), Marl, Germany. The petition proposes to amend the food additive regulations in § 177.1500 *Nylon resins* (21 CFR 177.1500), to provide for the safe use of poly-(trimethylhexamethylene terephthalamide) as components of articles intended for food-contact use.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4 (b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 18, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 4, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–20563 Filed 8–17–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95F–0210]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the expanded use of 2,2′-(2,5-thiophenediyl)-bis(5-*tert*-butylbenzoxazole) as an optical brightener in all polymers and adhesives intended for contact with food.